Latest Sales Growth News

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

Scentre Group has successfully tendered nearly 90% of its US$1.312 billion Non-Call 2030 Subordinated Notes, enabling full redemption and bolstering liquidity to A$3.2 billion. The group maintains its 2026 growth targets amid geopolitical uncertainty.

Coles Group posted a 3.1% lift in total sales for Q3 2026, driven by strong supermarket sales and a near 25% surge in eCommerce, while liquor sales fell amid soft consumer sentiment.

Scentre Group has successfully tendered 89% of its US$1.312 billion 2030 subordinated notes and plans to redeem the remainder, boosting liquidity to A$3.2 billion while maintaining 4% growth targets for 2026.

Freehill Mining’s aggregates business surged with a 59% jump in quarterly sales, while new copper project options promise to shift the company’s growth trajectory.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

AVADA Group reported a 14.9% rise in cash receipts for Q1 2026, underpinned by strong sales in Queensland and New South Wales, while completing a refinancing that improves liquidity and covenant headroom.

OMG Group posted a 44% increase in Q3 FY26 net sales, hitting a $6 million annual turnover milestone, while launching a dual matcha brand platform and securing national Woolworths distribution for new oat milk protein flavours.

Carma Limited surged past prior year sales with 1,344 units sold, boosted by rapid network expansion and improved reconditioning efficiency, while maintaining a solid cash position.

Mayne Pharma’s third quarter results show modest revenue growth but a sharp improvement in cash flow and earnings, powered by the strong launch of DistributeRx and robust Women’s Health sales.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.